Latisse approved for hypotrichosis of eyelashes
Allergan Announces U.S. Food and Drug Administration (FDA) Approval of LATISSE(TM) — First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes. New Prescription Product Increases Length, Thickness and Darkness of Eyelashes. – Allergan, Inc. (NYSE: AGN) announced that the U.S. Food and Drug Administration (FDA) has approved LATISSE(TM) (bimatoprost ophthalmic solution) 0.03% as a novel treatment for hypotrichosis of the eyelashes.